title: [Dopamine receptor agonists: new forms and new possibilities in the treatment of Parkinson's disease].
abstract: Main mechanisms of action of dopamine receptor agonists, efficacy of their use according to the results of earlier clinical trials and possible side-effects are discussed. The authors present their experience of prescription of rotigotine transdermal system in an open study of 30 patients with Parkinson's disease. The duration of the study was 8 weeks. There was a significant improvement of both motor and nonmotor (pain sensations, sleep, mood). The effective dose for treatment of initial stages was 4-6 mg daily and for the full-blown stage - 6-8 mg daily. The tolerability was good.
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: E A
authors.initials: EA
authors.lastname: Katunina
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: N V
authors.initials: NV
authors.lastname: Titova
authors.affiliation: City Policlinics, Moscow.
authors.forename: Yu N
authors.initials: YN
authors.lastname: Bezdolny
authors.affiliation: City Policlinics, Moscow.
authors.forename: R K
authors.initials: RK
authors.lastname: Shykkerimov
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: M G
authors.initials: MG
authors.lastname: Gasanov
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: S G
authors.initials: SG
authors.lastname: Burd
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: A V
authors.initials: AV
authors.lastname: Lebedeva
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: A N
authors.initials: AN
authors.lastname: Boiko
mesh_terms: D000279:Administration, Cutaneous; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009043:Motor Activity; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D018491:Dopamine Agonists; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; C047508:rotigotine